Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents
US12239655B2 · kind B2 · utility
0Cited by
2References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 27, 2018 |
| Grant date | Mar 4, 2025 |
| Priority date | — |
| Expiry date | Sep 8, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Nucleoside compounds, which in some embodiments include an alkynyl substituent at the 4′-position, compositions and methods for treating or preventing HIV and other viral infections, particularly where the virus is present in macrophages, microglia, and primary myeloid cells, and eliminating and/or treating infection in patients infected by these viruses, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.